Association between levosimendan, postoperative AKI, and mortality in cardiac surgery: Insights from the LEVO-CTS trial - 18/12/20
, Amanda S. Stebbins, MS b, Vignesh Raman, MD, MHS a, Brooke Alhanti, PhD b, Sean van Diepen, MD c, d, e, Matthias Heringlake, MD, PhD f, Stephen Fremes, MD, MSc g, Richard Whitlock, MD, PhD h, Steven R. Meyer, MD, PhD i, Rajendra H. Mehta, MD b, Mark Stafford-Smith, MD j, Shaun G. Goodman, MD, MSc d, k, John H. Alexander, MD, MHS b, Renato D. Lopes, MD, PhD bRiassunto |
Objectives |
We aimed to evaluate the association between levosimendan treatment and acute kidney injury (AKI) as well as assess the clinical sequelae of AKI in cardiac surgery patients with depressed left ventricular function (ejection fraction <35%).
Methods |
Patients in the LEVO-CTS trial undergoing on-pump coronary artery bypass grafting (CABG), valve, or CABG/valve surgery were stratified by occurrence and severity of postoperative AKI using the AKIN classification. The association between levosimendan infusion and AKI was modeled using multivariable regression.
Results |
Among 854 LEVO-CTS patients, 231 (27.0%) experienced postoperative AKI, including 182 (21.3%) with stage 1, 35 (4.1%) with stage 2, and 14 (1.6%) with stage 3 AKI. The rate of AKI was similar between patients receiving levosimendan or placebo. The odds of 30-day mortality significantly increased by AKI stage compared to those without AKI (stage 1: adjusted odds ratio [aOR] 2.0, 95% confidence interval [CI] 0.8-4.9; stage 2: aOR 9.1, 95% CI 3.2-25.7; stage 3: aOR 12.4, 95% CI 3.0-50.4). No association was observed between levosimendan, AKI stage, and odds of 30-day mortality (interaction P = .69). Factors independently associated with AKI included increasing age, body mass index, diabetes, and increasing baseline systolic blood pressure. Increasing baseline eGFR and aldosterone antagonist use were associated with a lower risk of AKI.
Conclusions |
Postoperative AKI is common among high-risk patients undergoing cardiac surgery and associated with significantly increased risk of 30-day death or dialysis. Levosimendan was not associated with the risk of AKI.
Il testo completo di questo articolo è disponibile in PDF.Mappa
| This abstract was presented at the 2019 AHA Scientific Sessions in Philadelphia, PA |
Vol 231
P. 18-24 - Gennaio 2021 Ritorno al numero
Articolo precedente
- Outpatient versus observation/inpatient management of emergency department patients rapidly ruled-out for acute myocardial infarction: Findings from the HIGH-US study
- Richard M. Nowak, Gordon Jacobsen, Alexander Limkakeng, William F. Peacock, Robert H. Christenson, James McCord, Fred S. Apple, Adam J Singer, Christopher R. deFilippi
- National trends and 30-day readmission rates for next-day-discharge transcatheter aortic valve replacement: An analysis from the Nationwide Readmissions Database, 2012-2016
- Charan Yerasi, Byomesh Tripathi, Yanying Wang, Brian J. Forrestal, Brian C. Case, Jaffar M. Khan, Rebecca Torguson, Itsik Ben-Dor, Lowell F. Satler, Hector M. Garcia-Garcia, William S. Weintraub, Toby Rogers, Ron Waksman
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?